---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-013188"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:57:26.503831+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx Q2 net loss $34M; positive XLRP gene therapy data; extends cash runway to Q4 2024

## Summary
- Net loss of $34.0M ($0.76/share) vs $20.1M ($0.46) in Q2 2021; license revenue up to $10.8M.
- Positive Phase 1/2 data for botaretigene sparoparvovec (AAV-RPGR) shows vision improvements in XLRP; Phase 3 Lumeos enrolling.
- Secured up to $100M senior secured financing from Perceptive secured by manufacturing facilities; $75M received at close.
- Cash and equivalents $72.1M at June 30 plus $15.9M Janssen receivable; cash runway to Q4 2024.
- R&D expenses increased to $24.0M from $15.2M due to manufacturing and clinical costs.

## SEC filing metadata
- accession: 0001558370-22-013188
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837022013188/0001558370-22-013188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837022013188/mgtx-20220811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-013188
- JSON: https://secwatch.observer/filing/0001558370-22-013188.json
- Plain text: https://secwatch.observer/filing/0001558370-22-013188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.